Related Experiment Video
Updated: Mar 31, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
A new class of drugs for systolic heart failure: The PARADIGM-HF study
Marwa A Sabe1, Miriam S Jacob1, David O Taylor1
1Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Abstract:
The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management

